Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.

We have conducted a Phase I trial to determine the maximum tolerated dose of CPT-11 together with a fixed dose of cisplatin in patients with advanced lung cancer, and the dose-limiting toxicities of this combination. Fourteen previously untreated patients with stage IIIB or IV disease were treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Takifuji, N., Nakagawa, K., Tamanoi, M., Nitta, T., Hirashima, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968602/
https://www.ncbi.nlm.nih.gov/pubmed/8398707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968602/
https://www.ncbi.nlm.nih.gov/pubmed/8398707

Ejemplares similares